Sumitomo Dainippon Pharma & BehaVR Announce Deal For Multiple Virtual Reality Digital Therapeutics

BehaVR, Inc., signed agreements with Japanese pharmaceutical company Sumitomo Dainippon Pharma Co. Ltd., (and its United States subsidiary Sunovion Pharmaceuticals Inc.) to develop and commercialize both prescription digital therapeutics (PDTs) and general wellness products that leverage virtual reality (VR) therapies. The focus is on treatment for social anxiety disorder, generalized anxiety disorder, and major depressive disorder. The products will be sold worldwide, including in the United States. The collaboration between Sumitomo Dainippon Pharma's wholly-owned U.S. subsidiary, Sunovion Pharmaceuticals Inc. and BehaVR, Inc., began in June 2020. The focus was on co-developing a wellness product for people . . .